PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Birkenfeld, A.L. ; Jordan, J.* ; Dworak, M.* ; Merkel, T.* ; Burnstock, G.*

Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts.

Pharmacol. Ther. 194, 132-144 (2019)
Postprint DOI PMC
Open Access Green
Despite significant therapeutic advances in heart failure (HF) therapy, the morbidity and mortality associated with this disease remains unacceptably high. The concept of metabolic dysfunction as an important underlying mechanism in HF is well established.Cardiac function is inextricably linked to metabolism, with dysregulation of cardiac metabolism pathways implicated in a range of cardiac complications, including HF. Modulation of cardiac metabolism has therefore become an attractive clinical target. Cardiac metabolism is based on the integration of adenosine triphosphate (ATP) production and utilization pathways. ATP itself impacts the heart not only by providing energy, but also represents a central element in the purinergic signaling pathway, which has received considerable attention in recent years. Furthermore, novel drugs that have received interest in HF include angiotensin receptor blocker-neprilysin inhibitor (ARNi) and sodium glucose cotransporter 2 (SGLT-2) inhibitors, whose favorable cardiovascular profile has been at least partly attributed to their effects on metabolism.This review, describes the major metabolic pathways and concepts of the healthy heart (including fatty acid oxidation, glycolysis, Krebs cycle, Randle cycle, and purinergic signaling) and their dysregulation in the progression to HF (including ketone and amino acid metabolism). The cardiac implications of HF comorbidities, including metabolic syndrome, diabetes mellitus and cachexia are also discussed. Finally, the impact of current HF and diabetes therapies on cardiac metabolism pathways and the relevance of this knowledge for current clinical practice is discussed. Targeting cardiac metabolism may have utility for the future treatment of patients with HF, complementing current approaches. (C) 2018 Published by Elsevier Inc.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
9.396
2.521
19
27
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Cardiac Metabolism ; Heart Failure ; Insulin Resistance ; Metabolic Therapy ; Purinergic Signaling; Activated-receptor-gamma; Cardiac Natriuretic Peptides; Left-ventricular Function; Ketone-body Metabolism; Fatty-acid-metabolism; Failing Human Heart; Late Sodium Current; Adenosine A(1); Double-blind; Substrate Metabolism
Sprache englisch
Veröffentlichungsjahr 2019
Prepublished im Jahr 2018
HGF-Berichtsjahr 2018
ISSN (print) / ISBN 0163-7258
e-ISSN 1879-016X
Zeitschrift Pharmacology & Therapeutics.
Quellenangaben Band: 194, Heft: , Seiten: 132-144 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1gb, England
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)
Institute of Pancreatic Islet Research (IPI)
POF Topic(s) 90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502400-001
G-502600-012
DOI 10.1016/j.pharmthera.2018.08.015
WOS ID WOS:000457951500008
Scopus ID 85054366531
PubMed ID 30149104
Erfassungsdatum 2018-09-18
[➜Korrektur melden]